Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist by Sepucha, Karen R et al.
Sepucha KR, et al. BMJ Qual Saf 2018;27:380–388. doi:10.1136/bmjqs-2017-006986380  
ReseaRch and RepoRting methodology
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjqs- 2017- 006986).




Department of Medicine, 
Harvard Medical School, 
Massachusetts General Hospital, 
Boston, MA 02114, USA;  
 ksepucha@ mgh. harvard. edu
Received 1 June 2017
Revised 21 September 2017
Accepted 31 October 2017
Published Online First 
21 December 2017
To cite: Sepucha KR, 
Abhyankar P, Hoffman AS, 
et al. BMJ Qual Saf 
2018;27:380–388.
 ► http:// dx. doi. org/ 10. 1136/ 
bmjqs- 2017- 006985
 ► http:// dx. doi. org/ 10. 1136/ 
bmjqs- 2017- 007019
 ► http:// dx. doi. org/ 10. 1136/ 
bmjqs- 2017- 007657
Standards for UNiversal reporting 
of patient Decision Aid Evaluation 
studies: the development of 
SUNDAE Checklist
Karen R sepucha,1 purva abhyankar,2 aubri s hoffman,3 
hilary l Bekker,4 annie leBlanc,5 carrie a levin,6 mary Ropka,7 
Victoria a shaffer,8 stacey l sheridan,9 dawn stacey,10,11 
peep stalmeier,12 ha Vo,13 celia e Wills,14 Richard thomson15
AbstrAct
Background Patient decision aids (PDAs) are evidence-
based tools designed to help patients make specific 
and deliberated choices among healthcare options. The 
International Patient Decision Aid Standards (IPDAS) 
Collaboration review papers and Cochrane systematic 
review of PDAs have found significant gaps in the 
reporting of evaluations of PDAs, including poor or 
limited reporting of PDA content, development methods 
and delivery. This study sought to develop and reach 
consensus on reporting guidelines to improve the quality 
of publications evaluating PDAs.
Methods An international workgroup, consisting of 
members from IPDAS Collaboration, followed established 
methods to develop reporting guidelines for PDA 
evaluation studies. This paper describes the results from 
three completed phases: (1) planning, (2) drafting and (3) 
consensus, which included a modified, two-stage, online 
international Delphi process. The work was conducted 
over 2 years with bimonthly conference calls and three in-
person meetings. The workgroup used input from these 
phases to produce a final set of recommended items in 
the form of a checklist.
Results The SUNDAE Checklist (Standards for UNiversal 
reporting of patient Decision Aid Evaluations) includes 
26 items recommended for studies reporting evaluations 
of PDAs. In the two-stage Delphi process, 117/143 
(82%) experts from 14 countries completed round 1 and 
96/117 (82%) completed round 2. Respondents reached 
a high level of consensus on the importance of the items 
and indicated strong willingness to use the items when 
reporting PDA studies.
Conclusion The SUNDAE Checklist will help ensure that 
reports of PDA evaluation studies are understandable, 
transparent and of high quality. A separate Explanation 
and Elaboration publication provides additional details to 
support use of the checklist.
IntroductIon
Patient decision aids (PDAs) are evidence-
based interventions designed to help 
people make informed and deliberated 
choices among healthcare options.1 2 At 
a minimum, PDAs provide accurate and 
unbiased information on options and 
relevant outcomes, help patients clarify 
their values and treatment preferences, 
and provide guidance in steps of decision 
making and deliberation.3 4  
The number and types of PDAs being 
developed, tested and reported in the liter-
ature have expanded considerably. The 
latest published update of the Cochrane 
systematic review of PDAs included 105 
randomised trials.3 Compared with usual 
care, using PDAs improves patients’ 
knowledge of and expectations about 
healthcare outcomes, reduces decisional 
conflict, increases decision quality and 
increases patient participation in decision 
making.3 The International Patient Deci-
sion Aid Standards (IPDAS) Collaboration 
has synthesised evidence across profes-
sional and disciplinary domains to develop 
quality standards for PDA development. In 
2013, the IPDAS Collaboration published 
12 papers updating the definitions, 
evidence and emerging research areas for 
all quality dimensions.5–16
The evidence base for PDA effective-
ness relies on accurate, complete and 
high-quality reports of evaluation studies. 
Despite the availability of reporting 
guidelines for a wide range of method-
ologies and interventions, investigators 
involved in the latest update of IPDAS 
and Cochrane reviews identified perva-
sive and significant gaps in published 
PDA evaluation studies. The problems 
included poor or limited reporting of 
the PDA content, development methods, 
delivery and evaluation methods.9 12 17 
For example, the description of PDAs was 
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often so limited that Cochrane reviewers had to obtain 
copies of the PDAs to determine their content and 
elements (eg, benefits and harms, patient stories, prob-
abilities).18 Further, a systematic review of measures 
used in PDA evaluations found that the description 
of the outcome measures used was often inadequate, 
particularly for the core outcomes related to decision 
quality and decision-making process outcomes.17
Without comprehensive and clear reporting of the 
PDA content and evaluation methods, there is limited 
evidence to understand which PDAs work and in what 
context. To address these gaps, an international work-
group was formed to develop and reach consensus on 
a set of reporting guidelines to improve the quality of 
manuscripts describing PDA evaluation studies.
Methods
The development of SUNDAE Checklist, or Stand-
ards for UNiversal reporting of patient Decision Aid 
Evaluations, followed the recommended process for 
developing and disseminating reporting guidelines 
put forth by EQUATOR (Enhancing the QUAlity 
and Transparency Of health Research).19 20 The 
development process has five phases: (1) planning phase, 
(2) drafting phase, (3) consensus phase, (4) dissemina-
tion phase and (5) maintenance phase (see figure 1). 
The first three phases are complete and reported in 
this manuscript. The phases are listed generally in the 
order they were initiated; however, the process was 
iterative within and between phases rather than purely 
sequential.
Planning phase
The purpose of this phase was to secure resources, 
conduct a needs assessment, review existing guidelines, 
and set a timeline and scope for the project. A reporting 
guideline workgroup (IPDAS-RG), led by KRS and RT, 
was set up to facilitate the guideline development. The 
cochairs received support and endorsement from the 
IPDAS Steering Committee, and then invited authors 
from each of the 12 IPDAS chapters to join the work-
group. Fourteen experts in PDA research representing 
a range of countries and disciplines (medicine, nursing, 
psychology, decision science and health services 
research) agreed to participate in the IPDAS-RG. The 
workgroup communicated through regular conference 
Figure 1 SUNDAE guideline development process to date. EQUATOR, Enhancing the QUAlity and Transparency Of health Research; IPDAS, International 
Patient Decision Aid Standards; SUNDAE, Standards for UNiversal reporting of patient Decision Aid Evaluations.
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calls and emails, and held three in-person meetings to 
enable discussion and debate over the course of the 
project.
The IPDAS-RG conducted a needs assessment to 
characterise the scope and range of issues that might 
be addressed with improved reporting of PDA evalu-
ation studies. Workgroup members examined each of 
the 12 IPDAS core dimensions, and summarised gaps 
in current reporting, the significance of the problem, 
evidence supporting the inclusion of specific items on 
PDA evaluations and the challenges to full reporting. 
We grouped gaps into major categories (eg, termi-
nology, decision aid components, research methods) 
and counted the number of chapters documenting a 
reporting gap in those categories.
Next, the workgroup reviewed and catalogued 
existing guidelines to determine whether the gaps could 
be addressed in full or in part by existing reporting 
guidelines. Relevant guidelines included CONSORT 
(CONsolidated Standards of Reporting Trials) and its 
extensions,21 TREND (Transparent Reporting of Eval-
uations with Nonrandomized Designs),22 STROBE 
(Strengthening The Reporting of Observational Studies 
in Epidemiology),23 TIDieR (Template for Intervention 
Description and Replication),24 CReDECI (Criteria 
for Reporting the Development and Evaluation of 
Complex Interventions in healthcare),25 SQUIRE 
(Standards for Quality Improvement Reporting Excel-
lence),26 and STaRI (Standards for Reporting Imple-
mentation studies of complex interventions).27
The group prioritised issues for inclusion in the 
guidelines when there was (1) evidence that the item or 
limited reporting of the item impacted outcomes and/
or interpretation of decision aid evaluation results; (2) 
inconsistent or limited reporting impacted the ability 
to conduct meta-analyses and/or systematic reviews 
to generate evidence; or (3) inconsistent or limited 
reporting, despite being included in existing reporting 
guidelines. The workgroup also agreed that the new 
guidelines would avoid overlap with other guidelines 
when possible, have language consistent with existing 
guidelines where items are similar, and focus on 
reporting studies of PDA evaluation. Although some of 
the items may be relevant for studies describing devel-
opment or implementation of PDAs, the focus is on 
evaluation studies. Once the need for reporting guide-
lines was clarified, the workgroup submitted proposals 
to governmental agencies and foundations to secure 
funding for the work.
drafting phase
The goal of this phase was to generate, test and refine 
an initial list of items to be included in the SUNDAE 
Checklist. As shown in figure 1, this phase had three 
steps. First, the workgroup used the findings from its 
needs assessment and review of existing guidelines to 
draft emerging items. Second, the workgroup came 
together in the first in-person meeting to review and 
comment on the items. The workgroup discussed 
the importance, relevance, overlap with existing 
guidelines and feasibility of reporting the requested 
information for each item. Two outside experts, lead 
authors of SQUIRE and TIDieR reporting guide-
lines, also attended the meeting and provided advice 
on guideline development methodology and process. 
The meeting resulted in consensus on the scope and 
purpose of the guideline, a draft of the 83 potential 
items to be included, a clear plan for next steps and 
allocation of tasks.
Third, IPDAS-RG members pilot-tested the draft of 
the 83 checklist items on nine published manuscripts 
of PDA evaluation studies. The selected publications 
were authored by the workgroup members in order 
to enable assessment of whether the information was 
available but not reported, or not available. Each 
article had two reviewers, the article’s author and an 
independent reviewer. The reviewers assessed whether 
and where each proposed item was reported and the 
ease of finding each item. If items were not present, 
reviewers assessed whether the information could 
feasibly be reported in the manuscript. Results of the 
pilot study were discussed among the workgroup, and 
revisions were made to the items to improve clarity 
and feasibility.
consensus phase
In this phase, we engaged a wide range of experts 
to review and comment on the draft items for the 
SUNDAE Checklist. First, we conducted a 90 min 
workshop at the International Shared Decision Making 
Conference (July 2015) to test the draft items, explore 
areas of disagreement and address any gaps. Attendees 
raised several issues that the IPDAS-RG had also 
discussed, including the potential overlap with existing 
guidelines, feasibility of including the information in 
an evaluation paper, potential overlap with work being 
done on developing guidelines for PDA development 
process28 and relationship to IPDAS.
Second, we conducted a two-stage modified 
Delphi survey online with a wider network of 
international stakeholders to help prioritise items 
and build consensus around the checklist.15 17 We 
recruited expert stakeholders worldwide, including 
(1) researchers who have published or planned to 
publish evaluation studies of PDAs, (2) clinicians 
and administrators who read and appraise the PDA 
studies, (3) patient/consumer advocates, (4) journal 
editors, (5) funders of PDA research, and (6) other 
reporting guideline developers. We sent invitations 
through the IPDAS Collaboration group, Shared 
Decision Making Facebook page and listserv, Society 
for Medical Decision Making newsletter, and 
through direct outreach to experts from workgroup 
members. We also used a snowball recruitment 
method to increase the respondent base by asking 
potential participants to forward the invitation to 
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their colleagues. We sent any subjects who expressed 
interest a link to the survey. We calculated response 
rates for the survey in each round by dividing the 
number of subjects who were sent the survey link by 
the number who completed the survey.
For the Delphi process, draft items were rated on 
a 9-point scale. The a priori rule of ‘disagreement’ 
was defined as having 30% or more responses in the 
lowest tertile (1–3) and 30% or more in the highest 
tertile (7–9). Because none of the items met the a 
priori threshold for disagreement, the workgroup 
flagged items that received less than 80% of impor-
tance ratings in the highest tertile (7–9) for review and 
discussion.29 Open-ended comments were reviewed 
and used to help interpret scores and revise items. In 
addition, we considered the evidence that the items 
impacted outcomes, the importance of the items for 
meta-analyses and/or systematic reviews and, for items 
that overlapped with other checklists, the importance 
of including the items due to misreporting or poor 
reporting in the existing literature. We considered 
weighting responses by stakeholder group, but decided 
not to because the majority of participants (82%) indi-
cated considerable expertise in two or more areas, 
making it difficult to assign participants to one stake-
holder group. We also examined whether responses of 
the IPDAS-RG workgroup respondents differed from 
others.
In round 1 of the Delphi, participants rated the 
importance (1=not at all, 9=extremely) and the 
clarity of wording (1=not at all, 9=completely) for 
51 items. For their ratings, participants were encour-
aged to consider whether the interpretation, analysis 
or appraisal of the paper would be adversely affected 
if the information was not included in the manu-
script. We also encouraged participants to provide 
open-ended comments on each item and at the end of 
the survey. At the second in-person meeting (March 
2016), the IPDAS-RG workgroup reviewed the round 
1 data and revised the items for round 2.
In round 2, participants were provided feed-
back from round 1 and asked to rate the revised 31 
items on the same 9-point importance scale and a 
9-point essential scale (1=not at all, 9=absolutely). 
The essential scale was introduced in an attempt to 
spread responses and differentiate between items that 
should remain in the checklist and those that might 
be considered for removal. Open-ended comments 
were invited. In round 2, the survey also elicited 
participants’ perceptions of the checklist, including 
their intention to use the ‘reporting checklist’, with 
five statements rated on a 5-point scale ranging from 
1=strongly agree to 5=strongly disagree. In the 
final in-person meeting (July 2016), the workgroup 
reviewed the data from round 2, discussed the ratings 




Reporting gaps identified by IPDAS chapters included 
lack of information about the PDA and its compo-
nents (n=7 chapters); lack of information about the 
PDA development process (n=4); lack of information 
about implementation and sustainability (n=3); lack 
of clarity of terminology (n=2); and lack of informa-
tion about measurement properties (n=1).
The review of relevant reporting guidelines found 
that the CONSORT, STROBE and TREND focused 
primarily on issues that would help readers under-
stand the overall study rationale and design; issues 
of bias; and results and their implications. TIDieR 
and CReDECI focused on intervention character-
istics, delivery and use. Finally, SQUIRE and STaRI 
addressed some of these same issues and additionally 
focused on intervention adaptation, delivery fidelity 
and potential financial conflicts. None of the existing 
reporting guidelines addressed issues of how an inter-
vention might be accessed, key features of intervention 
content and design relevant to the efficacy of decision 
aids, or a full set of methods to understand how and 
why the intervention works.
drafting phase
The workgroup generated a list of potential items 
and piloted the draft checklist on nine manuscripts. 
After this pilot, the workgroup removed, reworded 
and grouped items to reduce the number, and clarified 
the wording and organisation of items. Workgroup 
members then developed a brief rationale explaining 
each item, summarising evidence underlying the 
need for each item and outlining how accuracy and 
completeness of reporting support systematic reviews 
of the evidence for PDAs. The resulting draft checklist 
had 51 items and was used in round 1 of the Delphi 
process.
consensus phase
In the Delphi process, 117/143 (82%) invited partic-
ipants completed round 1. Round 2 was sent to all 
those who completed round 1. The majority, 96/117 
(82%), completed round 2. Respondents represented 
14 different countries, with about half from the USA 
(table 1). No item met the a priori definition for disa-
greement in either round. In round 1, 32/51 (63%) 
items had ≥80% of the importance ratings in the 
highest tertile (scores of 7–9), 17/51 (33%) items had 
60%–79% of ratings in the highest tertile, and 2/51 
(4%) items had 50%–59% of ratings in the highest 
tertile. Participant comments revealed concerns about 
lack of clarity of some items, the length of the check-
list, redundancy among items within the checklist and 
redundancy of items with other checklists.
The IPDAS-RG workgroup respondents (n=12) had 
similar scores to others (n=105). For the majority of 
individual items, 44/51 (86%), the median importance 
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scores were similar (±0.5 points), and as a result we 
did not separate the workgroup responses from the 
rest of the respondents. After detailed discussion of 
each item, the revised checklist had 31 items.
The ratings from round 2 indicated even higher 
consensus as 24/31 (77%) items had ≥80% of 
importance ratings in the highest tertile (7–9) and 
7/31 (23%) had 60%–79% of importance ratings 
in the highest tertile. There were fewer open-ended 
comments in round 2. Many comments were positive 
about the reduced length and clarity of items. Only a 
few raised concerns about redundancy. Table 2 pres-
ents the finalised SUNDAE Checklist with 26 items, 
and an accompanying glossary is included as an online 
supplementary appendix.
Willingness to use checklist
Virtually all respondents, 89/91 (98%), agreed that the 
checklist would improve the reporting of PDA studies, 
and 88/91 (97%) agreed they would recommend it to 
colleagues or students. The majority indicated high 
intentions to use it when preparing manuscripts (80/82, 
98%), designing studies (75/78, 96%) or supporting 
peer review of manuscripts (79/84, 94%).
dIscussIon
Key findings
The reporting guidelines included in the SUNDAE 
Checklist are the result of a rigorous, iterative devel-
opment process and are supported by substantial 
international consensus. While some of the items were 
included due to a strong evidence base linking their 
reporting to improved outcomes or reduced reporting 
bias, others were included to support systematic 
reviews and meta-analyses in efforts to advance the 
evidence base. Some items included in other reporting 
guidelines were adopted because they were specific to 
PDA evaluation studies and reflected factors likely to 
impact PDA effectiveness. The final guidelines reflect 
both evidence-based and expert consensus-based items 
to improve the reporting of evaluation studies of PDAs.
Purpose and scope
The purpose of SUNDAE is to improve the transpar-
ency, quality and completeness of reporting evalua-
tion studies of PDAs. Evaluation studies may include 
efficacy studies, comparative effectiveness studies or 
studies testing components of PDAs with a range of 
study designs. The checklist is not designed for manu-
scripts where the sole purpose is reporting the devel-
opment or the implementation of PDAs, nor the results 
of systematic reviews or meta-analyses of PDA studies. 
The checklist covers any decision support interven-
tion that meets the definition of PDA adopted by the 
Cochrane systematic review of PDAs or the IPDAS 
Collaboration,2 3 including decision aids designed 
for use during the consultation with the healthcare 
provider.
using the sundAe guidelines
The SUNDAE guidelines are intended to be used by 
researchers who are preparing to report a PDA evalu-
ation study. As is the case with other reporting guide-
lines, it may also be helpful for researchers to review 
the guidelines when designing the study protocol, to 
ensure the recommended items are collected, and thus 
able to be reported. Researchers are encouraged to 
review item 11 (table 2), which covers the description 
of the decision aid, as it is important that the interven-
tion meets the definition for a decision aid based on 
the Cochrane Collaborative Systematic Review defi-
nition.3 The guidelines represent recommendations 
for reporting, and there may be editorial and other 
constraints that limit authors’ ability to include all items 
in a paper. To overcome this challenge, researchers may 
reference other publications or sources if the relevant 
material is available elsewhere. Further, researchers are 
encouraged to consider using supplementary materials 
to maintain manuscript brevity while providing access 
to important details (eg, an online table describing 
key features of the decision aid and how it was devel-
oped). The accompanying Explanation and Elabora-
tion (E&E) document provides published examples of 







Age (years) 48±12 49±12
Sex
  Female 76 (65%) 63 (66%)
  Male 39 (33%) 32 (33%)
  Missing 2 (2%) 1 (1%)
Country of residence
  USA 60 (51%) 50 (52%)
  Canada 20 (17%) 14 (15%)
  UK 17 (14%) 13 (14%)
  The Netherlands 5 (4%) 5 (5%)
  Australia, Costa Rica, Denmark, Germany, Italy, 
Jordan, Romania, Spain, Sweden (<5 each)
13 (11%) 12 (12%)
  Unknown 2 (2%) 2 (2%)
Expertise (respondents could check more than 
one)
  Decision aid researcher, author, developer 86 (74%) NA
  Clinician, healthcare administration, decision 
aid user
56 (48%) NA
  Patient or consumer representative 4 (3%) NA
  Journal editor or funder 36 (31%) NA
  Guideline developer 9 (8%) NA
Number of publications
  0–1 15 (13%) 12 (12%)
  2–4 23 (20%) 17 (18%)
  5+ 79 (67%) 67 (70%)
*Table values are mean±SD for continuous variables and n (column %) for 
categorical variables.
†Numbers may not sum to total due to missing data, and percentages may not 
sum to 100% due to rounding.
NA, not available.
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Table 2 SUNDAE Checklist 
Section SUNDAE Checklist for evaluation studies of patient decision aids
Title/abstract
  1. Use the term patient decision aid in the abstract to identify the intervention evaluated and, if possible, in the title.
  2. In the abstract, identify the main outcomes used to evaluate the patient decision aid.
Introduction As part of standard introduction (the problem, gaps, purpose):
  3. Describe the decision that is the focus of the patient decision aid.
  4. Describe the intended user(s) of the patient decision aid.
  5. Summarise the need for the patient decision aid under evaluation.
  6. Describe the purpose of the evaluation study with respect to the patient decision aid.
Methods Studies with a comparator should also address items 7–13 for the comparator, if possible
  7. Briefly describe the development process for the patient decision aid (and any comparator), or cite other documents that describe the 
process. At a minimum include the following:
 ► participation of stakeholders in its development
 ► the process for gathering, selecting and appraising evidence to inform its content
 ► any testing that was done.
  8. Identify the patient decision aid evaluated in the study (and any comparator) by including:
 ► name or information that enables it to be identified
 ► date and/or version number
 ► how it can be accessed, if available.
  9. Describe the format(s) of the patient decision aid (and any comparator) (eg, paper, online, video).
  10. List the options presented in the patient decision aid (and any comparator).
  11. Indicate the components in the patient decision aid (and any comparator) including:
 ► explicit description of the decision*
 ► description of health problem*
 ► information on options and their benefits, harms and consequences*
 ► values clarification (implicit or explicit)*
 ► numerical probabilities
 ► tailoring of information or probabilities
 ► guidance in deliberation
 ► guidance in communication
 ► personal stories
 ► reading level or other strategies to help understanding
 ► other components.
  12. Briefly describe the components from item 11 that are included in the patient decision aid (and any comparator) or cite other 
documents that describe the components.
  13. Describe the delivery of the patient decision aid (and any comparator) including:
 ► how it was delivered (eg, by whom and/or by what method)
 ► to whom it was delivered
 ► where it was used
 ► when it was used in the pathway of care
 ► any training to support delivery
 ► setting characteristics and system factors influencing its delivery.
  14. Describe any methods used to assess the degree to which the patient decision aid was delivered and used as intended (also known 
as fidelity).
  15. Describe any methods used to understand how and why the patient decision aid works (also known as process evaluation) or cite 
other documents that describe the methods.
  16. Identify theories, models or frameworks used to guide the design of the evaluation and selection of study measures.
  17. For all study measures used to assess the impact of the patient decision aid on patients, health professionals, organisation, and 
health system:
 ► identify the measures
 ► indicate the timing of administration in relation to exposure to the patient decision aid and healthcare interventions.
  18. For any instruments used:
 ► name the instrument and the version (if applicable)
 ► briefly describe the psychometric properties, or cite other documents.
Results In addition to standard reporting of results:
  19. Describe the characteristics of the patient, family and carer population(s) (eg, health literacy, numeracy, prior experience with 
treatment options) that may affect patient decision aid outcomes.
  20. Describe any characteristics of the participating health professionals (eg, relevant training, usual care vs study professional, role in 
decision-making) that may affect decision aid outcomes.
Continued
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how authors have included this information in a parsi-
monious manner.30
relationship to other guidelines
Over recent years there has been a major international 
effort for reporting guidelines development, and 
this work has led to the creation of the EQUATOR 
network.19 20 The SUNDAE Checklist is registered on 
EQUATOR and was carefully designed to minimise 
repetition of items that are standard in other reporting 
checklists (eg, it does not include items that recommend 
reporting details of main findings/primary outcomes). 
Therefore, the SUNDAE Checklist is intended to 
supplement other reporting guidelines, not serve as 
a stand-alone checklist. It is expected that authors 
will consult other relevant reporting guidelines as 
needed (eg, CONSORT for randomised control trials, 
TREND for non-randomised trials of behavioural 
interventions, STROBE for cohort or case–control 
studies).21–23 Researchers preparing publications eval-
uating PDAs may also find it helpful to review guide-
lines for describing complex interventions (eg, TIDieR 
or CreDECI).24 25
Achieving consensus in multidisciplinary community
Research in PDAs exemplifies interdisciplinary applied 
science. The development, evaluation and implemen-
tation of PDAs draw on theories, knowledge and 
methods from several academic and professional disci-
plines, including, but not limited to, medicine, nursing, 
psychology, decision science, health informatics, imple-
mentation science and health services research. The 
workgroup members came from varied disciplines, as 
did the Delphi respondents, and the items that had the 
most varied ratings in the Delphi often marked ones 
that had different disciplinary approaches (eg, item 15, 
dealing with process evaluation; and item 16, dealing 
with use of theory, frameworks or models). The work-
group is eager to learn from users to continue to refine 
and advance the items, with a view to future modifi-
cation.
strengths and limitations
The key strengths of SUNDAE include the detailed 
and rigorous development process, the multidiscipli-
nary and international IPDAS-RG workgroup, and the 
consistently high ratings of items across a large inter-
national group of experts. There are some limitations, 
as with most reporting guidelines. Although there 
was wide engagement from international researchers 
in the Delphi process, the majority (80%) were from 
the USA, Canada and the UK, in part reflecting the 
leading countries involved to date in the development 
and evaluation of PDAs. There was limited input from 
consumers. As with other reporting guidelines, many 
of the guideline items are expert consensus-based, but 
this process drew on wide input from stakeholders 
with appropriate expertise.
Future work
The two remaining phases include (4) dissemination 
and (5) maintenance (figure 1). As part of the dissemi-
nation efforts, the SUNDAE Checklist will be available 
on multiple websites (including EQUATOR, IPDAS 
hosted by Ottawa Hospital Research Institute/Univer-
sity of Ottawa, Health Decision Sciences Center hosted 
by Massachusetts General Hospital, the US Agency for 
Healthcare Research and Quality, and the UK Health 
Foundation), and this guideline paper and the accom-
panying E&E will be open-access publications.
The IPDAS-RG encourages colleagues to use the 
checklist and to send the corresponding authors feed-
back on their experience. Those planning evaluation 
studies of PDAs may find the checklist valuable as 
Section SUNDAE Checklist for evaluation studies of patient decision aids
  21. Report any results on the use of the patient decision aid:
 ► how much and which components were used
 ► degree to which it was delivered and used as intended (also known as fidelity).
  22. Report relevant results of any analyses conducted to understand how and why the patient decision aid works (also known as process 
evaluation).
  23. Report any unanticipated positive or negative consequences of the patient decision aid.
Discussion As part of the standard discussion section (summary of key findings, interpretation, limitations and conclusion):
  24. Discuss whether the patient decision aid worked as intended and interpret the results taking into account the specific context of the 
study including any process evaluation.
  25. Discuss any implications of the results for patient decision aid development, research, implementation, and theory, frameworks or 
models.
Conflict of interest
  26. All study authors should disclose if they have an interest (professional, financial or intellectual) in any of the options included in the 
patient decision aid or a financial interest in the decision aid itself.
For any questions or comments on the SUNDAE Checklist 2017, please email decisions@partners.org.
*These components are needed to meet the definition of a patient decision aid.
SUNDAE, Standards for UNiversal reporting of patient Decision Aid Evaluations. 
Table 2 Continued 
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they are designing the study (as is the case with other 
reporting guidelines). Journal editors may consider 
the checklist to provide guidance for authors and for 
reviewers. The IPDAS-RG workgroup plans to gather 
feedback on feasibility and utilisation of the checklist 
and will reconvene in 2 years to assess the need for 
revision and updates.
The SUNDAE Checklist and the guidance in the 
accompanying E&E document will help to improve 
reporting of PDAs. Clear, comprehensive and consis-
tent reporting of evaluation studies will contribute to 
the evidence base and advance the collective under-
standing of the most effective ways to improve the 
quality of healthcare decisions.
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